Drugdevelopment-technology - drugdevelopment-technology.com - Drug Development Technology-Updates
General Information:
Latest News:
Takeda and Zinfandel begin Phase III trial of low dose pioglitazone 27 Aug 2013 | 04:00 am
Takeda Pharmaceutical Company and partner, Zinfandel Pharmaceuticals, have begun Phase III trial, also known as TOMMORROW, to assess investigational low dose pioglitazone.
GSK Phase III Crohn's disease study of vercirnon fails to meet end points 27 Aug 2013 | 04:00 am
GlaxoSmithKline's (GSK) Phase III study of an investigational CCR9 antagonist vercirnon in patients with moderate-to-severe Crohn's disease has failed to meet its primary endpoint of improvement in cl...
ISCO, Duke University to research stem cell treatment for Parkinson's disease 23 Aug 2013 | 04:00 am
International Stem Cell Corporation (ISCO) and Duke University have signed a master clinical research agreement to carry out clinical trials research in Parkinson's disease leveraging neural stem cell...
Catabasis begins Phase II trial of CAT-2003 for hypertriglyceridemia, hypercholesterolemia 23 Aug 2013 | 04:00 am
Catabasis Pharmaceuticals has begun a PATHWAYS I, Phase II trial of CAT-2003, a new chemical entity that is a SMART Linker conjugate, in patients with hypertriglyceridemia and hypercholesterolemia.
Tivicay (Dolutegravir) for the Treatment of HIV-1 Infection 22 Aug 2013 | 04:00 am
Tivicay (dolutegravir) is an integrase inhibitor indicated for the treatment of the HIV-1 infection in adults and children aged 12 years and above.
Otonomy reports positive Phase Ib data of OTO-201 in children undergoing ear tube placement surgery 22 Aug 2013 | 04:00 am
Clinical stage biopharmaceutical company Otonomy has reported positive data from a Phase Ib study of OTO-201, a sustained-release otic formulation of ciprofloxacin, in paediatric patients undergoing t...
Incyte reports results from Phase II proof-of-concept trial of ruxolitinib 22 Aug 2013 | 04:00 am
Incyte has reported top-line results from a Phase II proof-of-concept trial of an oral JAK1 and JAK2 inhibitor, ruxolitinib, as combination therapy with capecitabine in patients with refractory metast...
Adimab, Innovent partner for antibody-based therapeutic discovery programme 21 Aug 2013 | 04:00 am
Adimab, a monoclonal and bispecific antibody discovery company, and Chinese privately held biopharmaceutical company Innovent have partnered to discover, develop and commercialise an antibody-based th...
MacroGenics begins patient dosing in Phase I dose expansion cohort trial of MGA271 21 Aug 2013 | 04:00 am
Clinical-stage biopharmaceutical company MacroGenics has begun patient dosing in a Phase I dose expansion cohort trial of MGA271, an Fc-optimised monoclonal antibody that targets B7-H3-expressing tumo...
Selexys commences SUSTAIN Phase II trial of SelG1 in sickle cell patients with pain crises 20 Aug 2013 | 04:00 am
Selexys Pharmaceuticals has commenced a SUSTAIN Phase II trial to assess SelG1, an investigational anti-P-selectin humanised monoclonal antibody, in sickle cell patients with pain crises.
